Memory Impairment in Relapsing-Remitting Multiple Sclerosis Using a Challenging Semantic Interference Task
نویسندگان
چکیده
منابع مشابه
Working memory impairment in multiple sclerosis relapsing-remitting patients with episodic memory deficits.
Episodic memory is impaired in multiple sclerosis (MS) patients, possibly because of deficits in working memory (WM) functioning. If so, WM alterations should necessarily be found in patients with episodic memory deficits, but this has not yet been demonstrated. In this study we aimed at determining whether episodic memory deficits in relapsing-remitting MS are found in conjunction with impaire...
متن کاملInterferons in relapsing remitting multiple sclerosis.
BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined ...
متن کاملThalamic neurodegeneration in relapsing-remitting multiple sclerosis.
OBJECTIVE To define the extent of neuronal injury and loss in thalamic gray matter in patients with relapsing-remitting (RR) MS and to characterize how these neuronal pathologic changes are related to disease duration. METHODS The authors studied 14 patients with RRMS (Expanded Disability Status Scale score, mean 3.25, range 2.0 to 6.0) and 14 (8 men, 6 women) age-matched healthy controls. St...
متن کاملNatalizumab in relapsing-remitting multiple sclerosis.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). Based on its remarkable efficacy in reducing disease activity and reducing the risk of disability progession in RRMS, and the risk of a serious adverse event (progressive multifocal leukoencephalopathy [PML]), natalizumab was indicated in active RRMS, mostly as a sec...
متن کاملAlemtuzumab for relapsing-remitting multiple sclerosis.
In the past 10 years, the treatment options for patients with relapsing-remitting multiple sclerosis (RRMS) underwent some major changes. After relying on injectable interferon-beta preparations for quite some time, the advent of the first monoclonal antibody, natalizumab, followed by the first oral drug, fingolimod, improved the outcome of these patients and the possibilities to treat them mor...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neurology
سال: 2020
ISSN: 1664-2295
DOI: 10.3389/fneur.2020.00309